Assessing the Effect of Vitamin C Replacement as an Auxiliary Treatment for Anemia in Chronic Kidney Patients on Hemodialysis

Not Applicable

• Conditions: Anemia; C19.642.355; Chronic Renal Insufficiency; Hyperparathyroidism; Ascorbic Acid Deficiency; C15.378.071; C12.777.419.780.750; C18.654.521.500.133.115

• Registration Number: RBR-5jfjx9
• Lead Sponsor: Faculdade de Ciências Médicas

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-24
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Be part of a hemodialysis program for chronic kidney disease; Be on erythropoietin in any dose, to control anemia of chronic kidney disease; Perform at least three weekly hemodialysis sessions, with a minimum duration of 4 hours each session; Be assiduous at hemodialysis sessions

Exclusion Criteria

Do not use any therapies to control anemia of chronic kidney disease; Be a minor; Chronic ascorbic acid use; Failure of vascular access, such as catheters with low blood flow that prevent hemodialysis with flow above 250 ml / min; Critical worsening of health status, such as prolonged hospitalizations in intensive care units, patients undergoing major surgery with prolonged recovery or patients in palliative care for malignant neoplasms; Little attendance with frequent absences from hemodialysis sessions or undergoing hemodialysis during reduced hours or reduced doses; Any acute or chronic condition that limits the patient's ability to participate in the study, such as advanced heart or liver disease; Have a kidney transplant or recover kidney function in the middle of the study; Malnourished patients, with low body weight, those who use immunosuppressants, chemotherapy, antivirals or immunobiologicals; Patients with a hypersensitivity reaction to some of the research components, such as ascorbic acid or erythropoietin.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected to find the reduction in the dose of erythropoietin necessary to maintain hemoglobin between 10 and 12g / dL, verified by means of a complete blood count, from the observation of the variation of less than 25% in the weekly dose used in the pre and post intervention

Secondary Outcome Measures

Name	Time	Method
It is expected to find a reduction of more than 20% in the dose of Parathormone, verified by means of biochemical dosage, from the verification of the variation of 20% in relation to the dosage before the intervention;It is expected to find a reduction in the serum concentration of ferritin and an increase in transferrin saturation, above 20% of the previous values compared, verified by means of serum biochemical measurement.;To evaluate the incidence of respiratory and urinary infections from an individual approach and record in the medical record, analysis of the evolution of each patient and comparison with the incidence prior to the intervention.